News

The American Journal of Managed Care8d

In Study Across 15 Centers, 35% of Patients With MCL See Progression After CAR T-Cell Therapy

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression ...

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

BEIJING, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first ...
The Bakersfield Californian3d

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the ...
PharmaTimes13d

Scotland approves zanubrutinib for relapsed mantle cell lymphoma

Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment can now access ...